To find out if these findings also applied to other prostate cancer cell lines and more specifically if we would observe a difference between siFANCI-sensitive LNCaP and insensitive PC-3 cells, we analyzed mRNA levels of selected FA complex members in FANCI-silenced PC-3 cells using our RNA-sequencing data and RT-qPCR (Supplementary Figures S4B, S5A). This evidence concerns the gene FANCI and prostate carcinoma.